SEC Form 4 · accession 0001757533-26-000011
Sana Biotechnology, Inc. · SANA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alise Reicin
Director
Period of report
Jun 4, 2026
Accepted (ET)
Jun 5, 2026 · 4:38 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001770121
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.96 | Jun 4, 2026 | A | 90,000 | A | — | Jun 3, 2036 | Common Stock | 90,000 | 90,000 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.
Remarks
Exhibit List: Ex. 24 - Power of Attorney